2016 Fiscal Year Final Research Report
Development of a new immunotherapy activating both cytotoxic and helper T cells against bladder cancer
Project/Area Number |
26293353
|
Research Category |
Grant-in-Aid for Scientific Research (B)
|
Allocation Type | Partial Multi-year Fund |
Section | 一般 |
Research Field |
Urology
|
Research Institution | Kyushu University (2015-2016) Kumamoto University (2014) |
Principal Investigator |
Eto Masatoshi 九州大学, 医学(系)研究科(研究院), 教授 (90315078)
|
Co-Investigator(Kenkyū-buntansha) |
河野 吉昭 熊本大学, その他の研究科, 講師 (30593793)
|
Co-Investigator(Renkei-kenkyūsha) |
NISHIMURA Yasuharu 熊本大学, 大学院生命科学研究部, 教授 (10156119)
|
Project Period (FY) |
2014-04-01 – 2017-03-31
|
Keywords | 癌 / 免疫学 / トランスレーショナルリサーチ |
Outline of Final Research Achievements |
In this study, we have succeeded in identifying 4 long peptides (LPs) that comprise from 22-29 amino acids originated from Bladder cancer tumor-associated antigens (TAA). We confirmed the immunogenecity of LPs from Bladder cancer TAA (TAA-LP) by induction of TAA-LP-specific helper T (Th) cells from healthy donors. We could also detect type 1 Th (Th1) cells specific for TAA-LPs from Bladder cancer patients. Using transgenic mice expressing human HLA-A2, we next showed the induction of cytotoxic T cells (CTLs) specific for short peptides (SPs) from Bladder cancer TAA (TAA-SP), even after immunization with TAA-LPs, indicating the cross-presentation to Th cells and CTLs by TAA-LPs. We also succeeded in the enhancemant of CTLs against TAA-SPs when combined with LPs, Th clones, and anti-PD-1 mAb, implicating the new strategy of combination therapy with TAA-LPs. The above results have indicated that TAA-LPs are effective, and can be a new treatment option for patients with Bladder cancer.
|
Free Research Field |
泌尿器腫瘍学
|